News & Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders. Mr. Breeden’s decision to retire is not the result of any disagreement with the Company on any matters related to the Company’s operations,…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 31, 2026, STERIS plc (the “Company”) and Michael J. Tokich, the Company’s former Chief Financial Officer, entered into an amendment (the “Amendment”) to the Transition Agreement, dated August 5, 2025, between the Company and Mr. Tokich (the “Agreement”). In general, the Agreement governs the compensation and benefits that Mr. Tokich receiv…

of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 1, 2025, Dr. Richard Steeves notified STERIS plc (the “Company”) that he will retire from the Board of Directors (the “Board”) on the date of the Company’s Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on July 31, 2025. Therefore, Dr. Steeves will not stand for re-election to the Board at the Annual Meeting. Dr. S…

Other Events. On March 3, 2025, Isomedix Operations, Inc. (“Isomedix”), a subsidiary of STERIS plc (“STERIS” or the “Company”), entered into binding confidential term sheets with plaintiffs’ counsel (the “Term Sheets”), as well as settlement agreements with several plaintiffs currently scheduled for trial. The Term Sheets and the settlement agreements are expected to resolve substantially all of the claims for personal injury related to ethylene oxide (“EO”) that are currently pending in the…

Regulation FD Disclosure. Reference is made to the Current Report on Form 8-K dated April 11, 2024 of STERIS plc (“STERIS” or the “Company”) pursuant to which STERIS reported that STERIS Corporation, a wholly owned subsidiary of the Company, and certain affiliates, entered into an Equity Purchase Agreement to sell STERIS’s Dental business segment to HuFriedy Group Holding LLC, an affiliate of Peak Rock Capital LLC, for $787.5 million, subject to customary adjustments, and up to an additional…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 27, 2023, Dr. Esther Alegria was appointed to serve on the Compliance and Technology Committee and the Nominating and Governance Committee of the Board. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly author…

Regulation FD Disclosure Reference is made to the Current Report on Form 8-K dated December 20, 2021 of STERIS plc (“STERIS” or the “Company”) pursuant to which STERIS reported that subsidiaries of STERIS had entered into an Asset Purchase Agreement to sell STERIS’s Renal Care business to certain subsidiaries of Evoqua Water Technologies Corp., for cash consideration of approximately $196 million, subject to certain potential adjustments, including a customary working capital adjustment. The…

Regulation FD Disclosure On December 20, 2021, subsidiaries of STERIS plc (“STERIS” or “the Company”) entered into an Asset Purchase Agreement to sell STERIS’s Renal Care business to certain subsidiaries of Evoqua Water Technologies Corp., for cash consideration of approximately $196 million, subject to certain potential adjustments, including a customary working capital adjustment. The transaction is subject to customary closing conditions, including regulatory review, and is anticipated to…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 29, 2021, Paul E. Martin was appointed to serve on the Compliance and Technology Committee and the Compensation and Organization Development Committee of the Board. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto d…